替雷利珠单抗联合培美曲塞二钠及顺铂在晚期基因野生型肺腺癌治疗中的临床疗效及不良反应分析

Clinical Efficacy and Side Effects of Tirelizumab Combined with Pemetrexed Disodium and Cisplatin in Advanced Gene Wild-type Lung Adenocarcinoma

目的分析研究替雷利珠单抗联合顺铂、培美曲塞二钠在晚期基因野生型肺腺癌治疗中的临床疗效及不良反应。方法选取2019年12月到2021年6月我院收治的晚期基因野生型肺腺癌60例,将其分为两组,免疫联合化疗组予替雷利珠单抗联合顺铂、培美曲塞二钠治疗,单纯化疗组予顺铂联合培美曲塞二钠治疗,联合组45例,单纯化疗组15例,对比两组之间的疗效及不良反应。结果免疫联合化疗组的疾病控制率84.44%高于单纯化疗组的53.33%(P<0.05);免疫联合化疗组的中位总生存期12.09个月(95%可信区间8.41~13.96月)长于单纯化疗组7.23个月(95%可信区间3.86~10.42月),差异有统计学意义(P<0.05)。两组的不良反应比较,差异无统计学意义(P>0.05)。结论替雷利珠单抗联合顺铂、培美曲塞二钠在晚期基因野生型肺腺癌治疗中的临床疗效确切,安全性相对有保障,值得临床推广应用。

OBJECTIVE To analyze the clinical efficacy and side effects of tirelizumab combined with cisplatin and pemetrexed disodium in the treatment of advanced gene wild-type lung adenocarcinoma.METHODS 60 patients with advanced gene wild-type lung adenocarcinoma treated in our hospital from December 2019 to June 2021 were divided into two groups according to different treatment schemes.The immune combined chemotherapy group was treated with tirelizumab combined with cisplatin and pemetrexed disodium.The simple chemotherapy group was treated with cisplatin combined with pemetrexed disodium,45 cases in the combined group and 15 cases in the simple chemotherapy group.The therapeutic effect and side effects were compared between the two groups.RESULTS The disease control rate of immune combined chemotherapy group was 84.44%which was higher than that of simple chemotherapy group(53.33%),the difference was statistically significant(P<0.05);The median survival time of immune combined chemotherapy group was 12.09(95%CI:8.41-13.96)months,which was significantly longer than that of simple chemotherapy group(7.23〔95%CI:3.86-10.42〕)months)(P<0.05).There was no significant difference in adverse reactions between the two groups(P>0.05).CONCLUSION Tirelizumab combined with cisplatin and pemetrexed disodium is effective and safe in the treatment of advanced gene wild-type lung adenocarcinoma,which is worthy of clinical application.